[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36415
1. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Martins A, Cairoli H, Domínguez P, Martin S, Ortiz C, Potasznik J, Schenone N: [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant]. Arch Argent Pediatr; 2008 Jun;106(3):263-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant].
  • [Transliterated title] Nefromegalia: forma de presentación infrecuente de leucemia linfoblástica aguda en un lactante.
  • Nephromegaly in infancy may be due to several causes, being the most relevant: renal polycystic autosomic recessive disease, venous renal thrombosis, deposit diseases, kidney tumors, nephrotic congenital syndrome and neoplastic infiltration.
  • Although renal infiltration is relatively frequent in acute lymphoblastic leukemia, nephromegaly is an unusual form of presentation in this pathology.
  • Acute Lymphoblastic Leukemia is diagnosed, initiating the corresponding chemotherapic treatment.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695841.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


3. Martín Hernández JM, Donat Colomer J, Monteagudo Castro C, Fernández-Delgado Cerdá R, Alonso Usero V, Jordá Cuevas E: [Acral eruptive nevi after chemotherapy in children with acute lymphoblastic leukemia]. An Pediatr (Barc); 2006 Sep;65(3):260-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acral eruptive nevi after chemotherapy in children with acute lymphoblastic leukemia].
  • [Transliterated title] Nevos acrales eruptivos tras quimioterapia en niños afectados de leucemia linfoblástica aguda.
  • We report two cases of children with acute lymphoblastic leukemia who, after receiving chemotherapy, developed severe motor polyneuropathy, and sudden onset of multiple melanocytic nevi on the soles.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Foot Diseases / chemically induced. Nevus / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Skin Neoplasms / chemically induced


Advertisement
4. Dorantes-Acosta E, Arreguin-Gonzalez F, Rodriguez-Osorio CA, Sadowinski S, Pelayo R, Medina-Sanson A: Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report. Cases J; 2009;2:154
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report.
  • Acute leukemia, the most common form of cancer in children, accounts for approximately 30% of all childhood malignancies, with acute lymphoblastic leukemia being five times more frequent than acute myeloid leukemia.
  • Lineage switch is the term that has been used to describe the phenomenon of acute leukemias that meet the standard French-American-British system criteria for a particular lineage (either lymphoid or myeloid) upon initial diagnosis, but meet the criteria for the opposite lineage at relapse.
  • Many reports have documented conversions of acute lymphoblastic leukemia to acute myeloid leukemia.
  • Here, we report the case of a 4-year-old child with acute myeloid leukemia, which upon relapse switched to acute lymphoblastic leukemia.
  • The morphologic, phenotypic, and molecular features suggest the origin of a new leukemic clone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ther Clin Risk Manag. 2008 Apr;4(2):327-36 [18728851.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1315-20 [18418081.001]
  • [Cites] Nat Rev Immunol. 2008 Feb;8(2):95-106 [18204470.001]
  • [Cites] Trends Mol Med. 2007 Nov;13(11):470-81 [17981087.001]
  • [Cites] Nat Immunol. 2007 May;8(5):463-70 [17440452.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1963-6 [17008890.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Hematol Oncol Clin North Am. 1990 Aug;4(4):767-94 [2228896.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1712-9 [6352006.001]
  • [Cites] J Leukoc Biol. 2004 Jun;75(6):973-81 [14982952.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1503-18 [18548105.001]
  • (PMID = 19946525.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783110
  •  go-up   go-down


5. Dempsey RJ: Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All! Neurosurgery; 2009 Apr 01;64(4):N12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28175563.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Usvasalo A, Räty R, Knuutila S, Vettenranta K, Harila-Saari A, Jantunen E, Kauppila M, Koistinen P, Parto K, Riikonen P, Salmi TT, Silvennoinen R, Elonen E, Saarinen-Pihkala UM: Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica; 2008 Aug;93(8):1161-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia in adolescents and young adults in Finland.
  • BACKGROUND: Interest has recently been paid to adolescents and young adults with acute lymphoblastic leukemia, particularly because all reports so far published indicate that these patients have a better outcome when treated with pediatric rather than adult therapeutic protocols.
  • There are different biological subtypes of acute lymphoblastic leukemia with distinct features and prognoses; the distribution of these subtypes is not well known among adolescents.
  • We, therefore, studied acute lymphoblastic leukemia in adolescents and young adults aged 10 to 25 years in Finland.
  • DESIGN AND METHODS: This population-based study included 225 consecutive patients aged 10-25 years diagnosed with acute lymphoblastic leukemia during 1990-2004.
  • One hundred and twenty-eight patients (10-16 years) were treated with pediatric Nordic (NOPHO) protocols, and 97 patients (17-25 years) with Finnish Leukemia Group National protocols.
  • Patients with inferior outcome were those with a white blood cell count >or= 100 x 10(9)/L, the Philadelphia chromosome and MLL.
  • CONCLUSIONS: Unlike all previous studies, we found that the outcome of adolescents and young adults with acute lymphoblastic leukemia treated with pediatric or adult therapeutic protocols was comparable.
  • The success of the adult acute lymphoblastic leukemia therapy emphasizes the benefit of central referral of patients to academic centers and adherence to research protocols.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Blast Crisis. Child. Disease-Free Survival. Female. Finland. Humans. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Count. Male. Phenotype. Philadelphia Chromosome. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2008 Aug;93(8):1124-8 [18669975.001]
  • (PMID = 18556413.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Cheok MH, Pottier N, Kager L, Evans WE: Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):39-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics in acute lymphoblastic leukemia.
  • Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.
  • However, despite these high cure rates, the annual number of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.
  • These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):847-56 [10866211.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):857-65 [10866212.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):135-7 [11017062.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):164-72 [11159763.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):928-33 [11237013.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2293-301 [11304783.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2948-58 [11387368.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1262-8 [11435409.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1669-70 [11721042.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):930-42 [11733746.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:113-33 [11807167.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):391-7 [11988764.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Curr Opin Pharmacol. 2002 Dec;2(6):723-9 [12482737.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Haematologica. 2003 Mar;88(3):353-4 [12651279.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):518-21 [12652300.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Nat Med. 2003 May;9(5):510-1 [12724758.001]
  • [Cites] Science. 2003 Jul 4;301(5629):102-5 [12843395.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):577-80 [12972956.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Nat Rev Genet. 2003 Dec;4(12):1001-8 [14631360.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Pharmacogenomics J. 2004;4(1):66-72 [14647408.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):214-5 [14988717.001]
  • [Cites] Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R57-64 [14764619.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3347-58 [15060156.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3930-6 [15459215.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] J Steroid Biochem. 1987;27(1-3):201-8 [3501039.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):225-9 [1973780.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Annu Rev Genet. 1991;25:281-314 [1687498.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):377-83 [15765094.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1437-42 [12145682.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):407-17 [15862824.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):181-2 [11927832.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):895-905 [9001244.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1072-9 [15718463.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2482-7 [15781665.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1485-9 [15784872.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):277-85 [15864128.001]
  • [Cites] Blood. 2005 Jul 15;106(2):717-20 [15797993.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):878-82 [16041371.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Annu Rev Med. 2006;57:119-37 [16409140.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Leukemia. 2006 Jan;20(1):9-17 [16281070.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1113-6 [16870553.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1151-61 [16964229.001]
  • [Cites] Clin Pharmacol Ther. 2006 Nov;80(5):468-76 [17112803.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Science. 2007 Apr 27;316(5824):550-1 [17463274.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Nature. 2007 May 10;447(7141):161-5 [17495918.001]
  • [Cites] Nat Genet. 2007 Jul;39(7 Suppl):S7-15 [17597783.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13513-8 [17686970.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2261-71 [17616514.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2984-90 [18182569.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3692-700 [18096764.001]
  • [Cites] Blood. 2008 May 1;111(9):4496-9 [18285546.001]
  • [Cites] PLoS Med. 2008 Apr 15;5(4):e83 [18416598.001]
  • [Cites] PLoS One. 2008;3(5):e2144 [18478092.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):507-14 [18496130.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1792-803 [19066270.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):268-77 [10643153.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2004-13 [10688647.001]
  • (PMID = 19100367.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA036401-25; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA036401-25; United States / NCI NIH HHS / CA / R01 CA78224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 120
  • [Other-IDs] NLM/ NIHMS89418; NLM/ PMC2665795
  •  go-up   go-down


8. Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly MB, Wang Y, Qian Z, Jin J, Zhang Y, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen J: MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A; 2007 Dec 11;104(50):19971-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults.
  • To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale genome-wide microRNA (miRNA, miR) expression profiling assay and identified 27 miRNAs that are differentially expressed between ALL and AML.
  • Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML.
  • The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering most of the common cytogenetic subtypes, along with 10 normal control samples.
  • Furthermore, we found that overexpression of miR-128 in ALL was at least partly associated with promoter hypomethylation and not with an amplification of its genomic locus.
  • Taken together, we showed that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML, and that epigenetic regulation might play an important role in the regulation of expression of miRNAs in acute leukemias.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):545-53 [17585334.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Clin Lab Sci. 2004 Fall;17(4):235-45 [15559730.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):155-61 [15782179.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6296-305 [16155012.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2000 Mar;14(3):513-7 [10720153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Apr;33(4):331-45 [11921269.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):23-35 [12490758.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):305-16 [12649332.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Leuk Res. 1992 Dec;16(12):1155-63 [1465024.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):e38 [14973332.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Cell. 2005 Dec 2;123(5):819-31 [16325577.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Ann Hematol. 2006 Mar;85(3):139-63 [16391911.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1277-81 [16452179.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):435-43 [16766263.001]
  • [Cites] Methods Enzymol. 2006;411:134-93 [16939790.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2099-107 [17019734.001]
  • [Cites] Cell Cycle. 2006 Oct;5(19):2220-2 [17012846.001]
  • [Cites] Cell Cycle. 2006 Oct;5(19):2216-9 [17012848.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):953-60 [17163415.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):535-40 [17146476.001]
  • [Cites] Ann Hematol. 2007 May;86(5):311-27 [17375301.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4 Suppl 1):163-6 [17379102.001]
  • [Cites] Cell. 2007 May 4;129(3):617-31 [17482553.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • (PMID = 18056805.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA040046; United States / NCI NIH HHS / CA / CA40046
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2148407
  •  go-up   go-down


9. Bates J: Fighting fit. Nurs Stand; 2009 Oct 21;24(7):25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • I do not think he shouted 'Next!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28033816.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Duffin C: Court overrules 'unduly lenient' NMC misconduct judgement. Nurs Stand; 2005 Nov 02;20(8):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Court overrules 'unduly lenient' NMC misconduct judgement.
  • : A nurse who escaped punishment when she was found guilty of professional misconduct by the Nursing and Midwifery Council (NMC) is to face sanctions after all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27978254.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Uncovering Skills for Practice Carol Chapelow et al Uncovering Skills for Practice Nelson Thornes 184pp , £11.70 0 7487 9261 9 0748792619 [Formula: see text]. Nurs Stand; 2006 Jan 04;20(17):36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncovering Skills for Practice Carol Chapelow et al Uncovering Skills for Practice Nelson Thornes 184pp , £11.70 0 7487 9261 9 0748792619 [Formula: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990925.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. What you need to know about cannabis - understanding the facts David Emmett What you need to know about cannabis - understanding the facts and Graeme Nice Jessica Kingsley Publishers 128pp £12.99 978 1 84310 697 5 1843106973 [Formula: see text]. Nurs Stand; 2009 Jun 03;23(39):30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What you need to know about cannabis - understanding the facts David Emmett What you need to know about cannabis - understanding the facts and Graeme Nice Jessica Kingsley Publishers 128pp £12.99 978 1 84310 697 5 1843106973 [Formula: see text].
  • : This is an extremely readable and up to date book about all aspects of cannabis and cannabis use, amply illustrated with diagrams and photographs.
  • It is informative and balanced, as well as being well written, interesting and accessible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996850.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Bates J: Nursing fever. Nurs Stand; 2007 Mar 07;21(26):28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nursing fever.
  • : Job at risk? Facing redundancy?
  • Aren't we all?
  • Every now and then I daydream of early retirement: leisurely breakfasts with the papers, splashing out on luxury trips with my NHS pension.
  • Yes, the worry is making me hallucinate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967434.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Fowell M: 'damaged' nurses require support and not exclusion. Nurs Stand; 2010 Oct 27;25(8):32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'damaged' nurses require support and not exclusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28034104.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Black S: The power of compassion. Nurs Stand; 2008 Oct 22;23(7):70-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power of compassion.
  • : If you are thinking of becoming a nurse or have just embarked on a nursing course, one of the main characteristics you hope to bring to the role is likely to be compassion.
  • After all, compassion is what nurses do, isn't it?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006377.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Nurses have rights too. Nurs Stand; 2006 Nov 22;21(11):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nurses have rights too.
  • : Nursing is a profession that deals with the vulnerable.
  • Nurses have to be trusted by everyone they deal with, including their colleagues, peers and, above all, the public.
  • That overwhelmingly they are trusted, and that they rarely fail in their responsibilities and duties, is a testament to their professionalism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001881.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Allen D: Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up. Nurs Stand; 2006 Nov 08;21(9):25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up.
  • : Are you future-proofed? Me neither.
  • All I can deal with is the here and now.
  • But everywhere I look people are talking about future-proofing their practice.
  • GPs are at it, police officers, lawyers, teachers - even, I suspect, clairvoyants.
  • What is it all about and should nurses be doing it, too?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27986006.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M: BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7028
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.
  • We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.
  • Total nucleic acids were purified and subjected to two rounds of PCR analysis, with the first PCR designed to eliminate amplification of the wild-type, non-translocated ABL gene.
  • HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.
  • RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • 53% pts were treatement naïve, 72% had undergone nephrectomy and 83% had RCC with clear cell component.
  • With a median duration of treatment of 5 mo (range 0-12 mo), the investigator assessed ORR (CR+PR) is 27.2% (30% in clear cell RCC), SD 60.5% and Disease Control Rate (CR/PR + SD) 88%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hanrahan EO, Kim F, Lin HY, Tran HT, Ryan AJ, Krebs AD, Lee JJ, Johnson BE, Heymach JV, Kim ES: Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib. J Clin Oncol; 2009 May 20;27(15_suppl):9596
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib.
  • Lower baseline FACT-L scores (inferior QOL) were associated with higher pre-treatment plasma levels of INF-γ, IL-1RA, IL-6, IL-12, IL-15, TNF-α, RANTES, MIG, MIP-1β, MMP-9, bFGF, VEGF and sVEGFR-2 (all P<0.05).
  • Lower baseline TOI scores (inferior QOL) were also associated with higher pre-treatment plasma levels of multiple CAFs, including GCSF, HGF, INF-α, INF-γ, IL-2, IL-6, IL-8, IL-12, IL-15, TNF-α, bFGF, sVEGFR-2 and VEGF (all P<0.05).
  • Trends for FACT-L were similar, but did not reach statistical significance.
  • CONCLUSIONS: High plasma concentrations of multiple CAFs pre-treatment in patients with NSCLC correlated with inferior QOL, and rises in these factors during treatment were associated with worsening QOL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol; 2009 May 20;27(15_suppl):10015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The PPTP includes a molecularly characterized in vitro panel of cell lines (n = 27) and in vivo panel of xenografts (n = 60) representing most of the common types of childhood solid tumors and childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: GSK923295A demonstrated potent in vitro activity against the PPTP cell line panel with a median IC50 of 27 nM (range 12 nM to > 10 μM).
  • Objective responses were noted in 13 of 35 xenografts, including 9 with maintained complete responses (MCR), 3 with complete response (CR), and 1 with partial response (PR).
  • For the neuroblastoma panel, the best response was progressive disease (PD) with growth delay compared to controls (PD2 response), which was observed in 5 of 6 xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962529.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC: Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. J Clin Oncol; 2009 May 20;27(15_suppl):9563
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients.
  • This study examined the relationship between PR fatigue and QOL as well as cancer-related symptoms (CRS) in 43 North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials.
  • Pts' QOL assessment included a single-item overall QOL and associated QOL domains measured by numerical analogues, the Profile of Mood States (POMS), and PR symptom assessment measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Crino L, Mezger J, Griesinger F, Zhou C, Reck MM: MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8043
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Primary endpoint was safety; secondary endpoints included time to disease progression (TTP) and overall survival (OS).
  • Pts with untreated locally advanced, metastatic or recurrent non-squamous NSCLC (ECOG PS 0-2) received Bv (7.5 or 15mg/kg) with standard chemotherapy for up to six cycles, then non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.
  • Trial data were not deemed mature enough to provide efficacy results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Bloomfield CD: Importance of genetic heterogeneity in curing adult acute leukemia (AL). J Clin Oncol; 2009 May 20;27(15_suppl):s1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of genetic heterogeneity in curing adult acute leukemia (AL).
  • Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), that required separate treatment.
  • The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.
  • Recognition of increased sensitivity of a genetic subtype of AML to high-dose cytarabine (HiDAC) has increased the cure rate of core-binding factor (CBF) AML from <10%-25% to 55%-60%.
  • Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.
  • New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Hauser KA, Karafa M, Seyidova-Khoshknabi D, Davis MP, Walsh D: Prevalence and risk factors of vitamin D insufficiency in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9581
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data extracted: demographics (age, gender, race), cancer site (primary and metastatic, ICD-9 codes) and first 25 hydroxy vitamin D level [25OHD] during the study period.
  • Clinical factors were compared between those tested for 25OHD vs not, and those insufficient (25OH D ≤30ng/ml) vs not (25OH D >31ng/ml) by Chi square or T-tests.
  • They were more likely female (66% vs 47%), and to have breast, hepatobiliary, skin or thyroid cancer, than those not tested (both p<0.001).
  • Insufficiency was associated with male gender, race (African American), month of test (Feb-Apr, Oct), cancer type (hepatobiliary, genitourinary, pancreas, upper gastrointestinal), metastatic disease, low albumin, high bilirubin and AST, and lack of antineoplastic or vitamin D medication (all p<0.01).
  • Multivariable predictors were cancer type, test month, African American race, low albumin, and lack of antineoplastic or vitamin D medication (all p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Policzer J, Kinzbrunner B, Tanis D: Seasonal mortality in terminally ill cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):6575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we compare seasonal variation in death rates for terminally ill cancer patients to terminally ill patients who are "frail," i.e., those with neurodegenerative disease, general debility, or chronic heart failure.
  • The 72,066 records were analyzed using a three-way analysis of variance (season, place of care, diagnosis) with Bonferroni correction for post-hoc comparisons.
  • For cancer patients, this seasonal variation was not observed in any place of care (all p > 0.05).
  • These include a smaller "symptom burden" than frail patients, who frequently have comorbid disease(s) and who are often unable to make their needs known; less compromised immune systems; more aggressive medical treatment; better nutrition; a strong support system (particularly from family and caregivers); and increased sensitivity to factors that may prolong survival, e.g., timely immunizations and even the avoidance of crowds in winter months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963828.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Tercyak K, Peshkin B, DeMarco T, Schneider K, Valdimarsdottir H, Garber J, Patenaude A: Parental decisions and outcomes regarding disclosing maternal BRCA1 and 2 test results to children. J Clin Oncol; 2009 May 20;27(15_suppl):9582
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Predictors of maternal disclosure to children included not being a BRCA1/2 mutation carrier, older child age, stronger intentions to disclose, more favorable attitudes toward pediatric BRCA1/2 testing, a more open parent-child communication history, and a decisional balance favoring disclosure (all p's<.05).
  • When examined simultaneously, mothers who were not mutation carriers (OR=4.02, 95% CI=1.35, 11.94), mothers of older children (OR=1.30, 95% CI=1.13, 1.49), and those with stronger intentions to disclose (OR=1.39, 95% CI=1.10, 1.76) were more likely to communicate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963706.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sampat KR, Garcia-Gutierrez V, Rossi A, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G: Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7067
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia.
  • : 7067 Background: Little is known regarding the prevalence and natural history of pericardial disease in patients with leukemia.
  • Although a direct causal relationship has not been established yet, this complication may have a significant impact for the future development of this class of drugs.
  • To study this issue, we retrospectively analyzed a large cohort of patients with leukemia, who were evaluated at MD Anderson Cancer Center (MDACC), to determine the prevalence, timing, and characteristics of PEf in leukemia.
  • METHODS: We reviewed 3,327 patients with acute myeloid leukemia (AML, N = 1,809, 54%), acute lymphocytic leukemia (ALL, N = 494, 15%), or myelodysplastic syndrome (MDS, N =1,024, 31%), who were seen at MDACC from August 2003 to July 2008.
  • Data regarding diagnosis, timing, effusion size, and prior therapy was collected in the 401 patients (20.2%) that had echocardiographic evidence of PEf.
  • In the 401 total patients with PEf, 22.8%, 25.0%, and 18.4% (p = 0.33) of these effusions were found before treatment in the three disease categories, respectively.
  • The rest occurred after some form of chemotherapy, accounting for 77.2%, 75.0%, and 81.6% (p = 0.73) of the total PEf by disease, respectively.
  • CONCLUSIONS: PEf are relatively common in patients with leukemia at initial presentation and are usually asymptomatic.
  • Their incidence increases with therapy administration although it appears that this is not a process related to specific classes of treatment or type of leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961462.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Olmos D, Allred A, Sharma R, Brunetto A, Smith D, Murray S, Barker D, Taegtmeyer A, de Bono J, Blagden S: Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3536
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stable disease >5m has been observed in 2 esophageal cancer pts.
  • An MTD has not yet been defined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Smith J, Benjamin M, Yim JH, James RL, Ramanathan RK, Anthony SP, Borad M, Bay RC, Piper BF, Tibes R: Prospective evaluation of patient perceptions and willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. J Clin Oncol; 2009 May 20;27(15_suppl):6587
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary purposes included correlating test number and type with demographics, prior test experience, coverage, and inconvenience.
  • METHODS: Exploratory correlative study using a multi-item self-report questionnaire to measure pts willingness (0-10 scale, 0 = not willing, 10 = very willing) to undergo imaging (e.g., MRI, ECHO), invasive (e.g., tumor, skin biopsies [bx]) and less invasive tests (e.g., blood, urine).
  • Surprisingly, inconvenience and prior negative experiences for the more invasive tests (e.g., skin bx) did not negatively affect willingness to undergo these tests in the future as opposed to most imaging studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients were ineligible and did not receive study drug.
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.
  • PK and PD data were not available for this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vicus D, Beiner M, Klachook S, Le L, Ginsburg O, Laframboise S, Mackay H: Dysgerminoma of the ovary 35 years on: A single institutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16523
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 40 pts (62.5%) presented with FIGO stage IA disease; 3 (4.7%) stage IB; 6 (9.4%) stage IC; 2 (3.1%) stage II; and 13 (20.3%) at stage III, 1 unknown.
  • 17 pts received chemotherapy, 15 adjuvant and 2 for residual disease (all post 1988); 8 for stage I, 1 for stage II, and 8 for stage III.
  • 6 (9.2%) pts recurred all within 19 months of initial diagnosis.
  • 5 of the 6 pts that recurred had stage IA disease treated with a unilateral oophorectomy, 1 received adjuvant EP.
  • 1 pt with stage IIIC disease recurred following bilateral oophorectomy + hysterectomy and radiotherapy.
  • Treatment of recurrent disease was by salvage surgery and chemotherapy (3 pts), radiotherapy (2 pts), and EP (1 pt).
  • Recurrences occured within 2 years of diagnosis and are treatable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Latreille J, Samson A, Tran U, Mimeault C, Boily C, Laflamme B, Loutfi A: Implementation of an integrated cancer care network. J Clin Oncol; 2009 May 20;27(15_suppl):e17564
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2004, a team evaluation process was initiated by the Direction de la lutte contre le cancer (ministry of health) to help implement this program.
  • Those who did not succeed had one year to reapply.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Holmström R: Beyond black and white. Nurs Stand; 2010 Oct 13;25(6):62-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 'Assumptions based on a patient's appearance may well have an effect on clinical judgements - but that is not all,' says RCN diversity and equalities co-ordinator Wendy Irwin.
  • 'If patients do not feel understood at a time when they are at their most vulnerable, that is an important issue of dignity and one that nurses specifically should keep in mind. '

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029951.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Ward to board leadership. Nurs Stand; 2009 Oct 14;24(6):24-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ward to board leadership.
  • : Nursing directors are supposed to ensure that clinical quality features frequently on the agendas of NHS board meetings and is monitored at board level.
  • On the face of it, nurse directors are ideally placed to promote clinical quality.
  • After all, nurses and midwives are seen as key to providing quality care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28080695.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Pay cut after 'best year'? Nurs Stand; 2006 Nov 01;21(8):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pay cut after 'best year'?
  • : When governments boast about how well the health service is performing under their stewardship - usually the number of patients treated and how quickly - they are really describing the achievements of staff in hospitals and the community.
  • After all, no minister has ever actually walked into a treatment centre or a patient's home and delivered care themselves.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010483.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Terms of endearment. Nurs Stand; 2008 Dec 03;23(13):13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terms of endearment.
  • : Some nurses address their older patients as 'love' or 'dearie' simply as a term of endearment.
  • Others say it because they have forgotten the names of their patients.
  • But what is clear from new Nursing and Midwifery Council (NMC) guidance is that no nurse should be using those terms at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010406.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Have a look at the other side of the work/life balance. Nurs Stand; 2007 Aug 01;21(47):32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Have a look at the other side of the work/life balance.
  • : Has nursing become the most selfish profession of all?
  • We constantly moan about night shifts, how staff shortages and deficits are detrimental to quality patient care and nursing intervention, and how this limits our ability to provide the highest standards of nursing.
  • On the other hand, I cannot help but notice how we seem to forget to look after each other when it comes to shift allocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001636.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Reservists seek more support from managers and staff. Nurs Stand; 2008 Oct 22;23(7):12-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Being a reservist in the Royal Navy is not all about spending weekends on ships or training for combat.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006359.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text]. Nurs Stand; 2005 Dec 07;20(13):36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text].
  • : William Blows begins the introduction to this book by stating: 'Life is all about biology.
  • ' He believes most of us are guilty of seeing biology as just a subject, rather than an actual living and happening event around us and driving us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001787.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Newnham D: Outsidein - the euro health insurance card expires. David Newnham thinks he knows why. Nurs Stand; 2009 Apr 08;23(31):26-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outsidein - the euro health insurance card expires. David Newnham thinks he knows why.
  • : Shock, horror, read all about it - millions of European Health Insurance Cards (EHICs) are about to expire.
  • Feckless Brits face Euro- holiday hell.
  • Department of Health (DH) calls in TV doctor.
  • Honestly, anyone would think avian flu had suddenly landed at Gatwick.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996519.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Bates J: Quality is key. Nurs Stand; 2009 Apr 29;23(34):27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is overambitious, I know, and unlikely to happen, but if I do not at least have a target then there is no hope at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991067.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. What price this pay rise? Nurs Stand; 2007 Mar 07;21(26):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What price this pay rise?
  • : There was outrage when a trust suggested that staff should work a day for free to help its finances.
  • And rightly so.
  • But now it seems the same principle is being applied nationally.
  • That really is the only conclusion to be drawn from the decision to stage your 2007 pay award.
  • After all, an independent review body looked at all the evidence, including ministers' arguments about affordability, and decided that a fair award this year would be 2.5 per cent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967387.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Szczepanska S, Scullion J, Holyoake DD, Brown J: Stars fall to earth. Nurs Stand; 2005 Jan 12;19(18):26-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Everyday concerns count more As an NHS employee, I must admit I could not care less about star ratings.
  • I certainly do not feel I should leave my trust to work in another one with a higher star rating.
  • I do not feel stars reflect performance accurately at all.
  • If a hospital is failing in certain areas why not just point it out and let it make changes?
  • And as long as I survive the surgery, am nursed in a clean ward and do not catch an infection, I do not care how the trust is rated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985052.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Al-Khyatt W, Syed BM, Morgan DA, Cheung KL: Primary endocrine therapy for early operable primary breast cancer in elderly women: A large series from a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):630
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had disease assessable for response according to UICC criteria, and had treatment for ≥6 months unless the disease progressed prior.
  • When the disease progressed, some patients received further lines of therapy and the overall results are summarised (Table).
  • CR: complete response; PR: partial response; SD: stable disease; CB: clinical benefit = CR + PR + SD; PD: progressive disease; DoCB: duration of CB; TTP: time to progression (all in months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961443.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Xu Y, Fan J, Yang X, Zhou J, Qiu S: High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22121
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma.
  • : e22121 Background: To investigate the prognostic values of putative hepatic stem/progenitor cells (HSCs/HPCs) biomarkers in hepatocellular carcinoma (HCC) patients.
  • METHODS: Fourteen biomarkers related with HSCs/HPCs or tumor angiogenesis were assessed by qRT-PCR and then validated by tissue microarrays (TMAs) in three independent cohorts of HCC patients underwent curative resection (n=67, 314 and 73).
  • RESULTS: Most of the biomarkers were found over-expressed in recurrent HCC patients by qRT-PCR.
  • HSCs/HPCs biomarkers cytokeratin 19, ABCG2, CD133, Nestin, CD44 and angiogenesis agents CD34, VEGF and PD-ECGF, were confirmed as significant predictors for overall survival (OS) and/or relapse-free survival (RFS) in TMAs analysis.
  • Compared with the low HSCs/HPCs profile group, patients with high HSCs/HPCs profile had significantly lower OS and RFS (p<0.0001), expressed higher VEGF levels (p = 0.012) and microvessel density (MVD, determined by CD34 immunostaining, p = 0.030).
  • Based on Cox regression, a simplified model including CD133, CD44, Nestin, and MVD was constructed and confirmed as an independent predictor for OS (p<0.0001) and RFS (p<0.0001), regardless of alpha-fetoprotein level, tumor stage and recurrence time (p<0.0001 for all).
  • CONCLUSIONS: High expression levels of HSCs/HPCs biomarkers are related to tumor angiogenesis and poor prognosis of HCC.
  • The simplified model based on HSCs/HPCs and tumor angiogenesis profile can be used to classify HCC patients with high risk of tumor recurrence after operation.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tucker K Esq: End-of-life care: Empowering cancer patients with information and choices. J Clin Oncol; 2009 May 20;27(15_suppl):e20739
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] End-of-life care: Empowering cancer patients with information and choices.
  • : e20739 Background: Terminally ill patients want information and choices, including aid in dying, as they confront death due to cancer and other terminal illnesses.
  • Physicians treating such patients want to feel safe in having candid conversations with patients about their wishes and to provide aid in dying when appropriate.
  • METHODS: Review the law governing end of life decision making, including aid in dying.
  • Review the data from Oregon, which has more than 10 years experience with a regulated practice.
  • Review what has been learned in OR, and how that is transferring to other states making aid in dying an end of life option.
  • RESULTS: Oregon's experience shows that when aid in dying is a legal option for mentally competent terminally ill patients overall end of life care improves.
  • Conversations between physicians and patients are more open and candid; Referrals to hospice increase and occur earlier; clinician enrollment in CE for pain and symptom management increase; rx of strong pain medication increase; more patients die at home; patients are comforted to have aid in dying as an option; there is no negative impact on the practice of medicine.
  • CONCLUSIONS: Terminally ill patients should be able to recieve comprehensive counseling about all end of life options.
  • There is a growing trend of support for expanding end of life options to include aid in dying for mentally competent terminally ill patients who find themselves trapped in an unbearable dying process.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962041.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Sleight DA, Mavis BE: Study Skills and Academic Performance among Second-Year Medical Students in Problem-Based Learning. Med Educ Online; 2006 Dec;11(1):4599
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre-existing differences related to academic achievement and study strategies were found when students at the top, middle and bottom of exam performance were compared.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28253787.001).
  • [ISSN] 1087-2981
  • [Journal-full-title] Medical education online
  • [ISO-abbreviation] Med Educ Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Wilson CR, Sherritt L, Knight JR: Teaching Residents about Child Neglect and Parental Alcoholism: A Controlled Pilot Study. Med Educ Online; 2005 Dec;10(1):4381
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pre/post change in scores on a knowledge quiz and attitude scale.
  • The two groups did not differ significantly in mean pre-post change on the knowledge quiz or attitude scale.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28253138.001).
  • [ISSN] 1087-2981
  • [Journal-full-title] Medical education online
  • [ISO-abbreviation] Med Educ Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Child Neglect / Medical Education / Pediatrics / Substance Abuse
  •  go-up   go-down


50. Drabkin HA, Sharma G, Costa LJ, Korch C, Gemmill RM: Synergistic growth inhibition of RCC and NSCLC cell lines by sorafenib plus vorinostat and induction of angiogenic genes by ER stress. J Clin Oncol; 2009 May 20;27(15_suppl):e16114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic growth inhibition of RCC and NSCLC cell lines by sorafenib plus vorinostat and induction of angiogenic genes by ER stress.
  • : e16114 Sorafenib, vorinostat and the combination were examined in 34 RCC and NSCLC cell lines.
  • Changes in phospho-ERK and AKT were not predictive of growth inhibition, whereas frequent inhibition of cyclin D1 and upregulation of p21<sup>Waf1</sup> was observed.
  • Importantly, sorafenib at 8 μM, but not lower doses, induced ER stress in these cell lines and thapsigargin or tunicamycin treatment recapitulated many, but not all, of the observed angiogenic gene responses to sorafenib.
  • In summary, sorafenib plus vorinostat potently inhibits the in vitro growth of RCC and NSCLC cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963311.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Trejo Amador U, Granados Cosme JA, Ortiz Hernández L, Delgado Sánchez G: [Social Differences in Proper Detection of Cervical Uterine Cancer among Employees at a University in Mexico City]. Rev Esp Salud Publica; 2005 Jun 01;79:403-414
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diferencias sociales de la detección oportuna de cáncer cérvico uterino en las mujeres trabajadoras de una Universidad de la Ciudad de México.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28272388.001).
  • [ISSN] 2173-9110
  • [Journal-full-title] Revista espanola de salud publica
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Cervical cancer / Inequalities / Life style / Mexico / Social conditions / Socioeconomic factors / Socioeconomic level.
  •  go-up   go-down


52. Kamoi K, Kawauchi A, Miki T, Aron M, Remer E, Haber G, Berger A, Crouzet S, Ricardo B, Gill I: Laparoscopic renal cryoablation: Risk factor analysis to predict oncologic outcomes with minimum 5-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):5094
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the 69 patients with biopsy-proven renal cell cancer (median follow-up 81 mos; range 60-132 mos), 5-year overall, disease-specific, and disease- free survival was 75%, 92%, and 82%, respectively, while 10-year overall, disease-specific, and disease-free survival was 46%, 83%, and 79%, respectively.
  • Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.
  • Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.
  • Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Rousseau M, Guevremont P, Chasen M, Spicer J, Eckert E, Alcindor T, Ades S, Ferri LE: The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? J Clin Oncol; 2009 May 20;27(15_suppl):9613
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All received dietary counseling and were closely monitored for signs/ symptoms of malnutrition with serial (baseline, after 1<sup>st</sup> cycle, pre-surgery) Body Mass Index (BMI), albumin, dysphagia scores (0 best - 4 worse), and quality of life (FACT-E).
  • A small decrease in BMI was noted, however serum albumin did not significantly decrease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Casali PG, Stacchiotti S, Palassini E, Marrari A, Negri T, Morosi C, Messina A, Pastorino U, Gronchi A, Pilotti S: Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT). J Clin Oncol; 2009 May 20;27(15_suppl):10571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When medical therapy is needed, cytotoxic chemotherapy is poorly active in this sarcoma subtype, but the activity of bevacizumab + temozolomide was recently reported.
  • RESULTS: Between 3 weeks and 3 months, 4 in 5 patients had a tumor response according to Choi's criteria (all with RECIST stable disease) .
  • In two, surgery of residual disease is planned, and downstream RTK signaling analysis will be performed on the specimen.
  • This might help address an unmet clinical need in a rare sarcoma subtype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Wiechmann L, Jacks L, Patil S, Stempel M, Morrow M: Impact of molecular subtype on presenting characteristics of T1a,b tumors. J Clin Oncol; 2009 May 20;27(15_suppl):11111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of molecular subtype on presenting characteristics of T1a,b tumors.
  • There is interest in the impact of molecular subtype on outcome in T1a,bN0M0 tumors, a group thought to have good prognosis and to be amenable to breast conservation.
  • METHODS: Subtypes were classified using IHC as Lum A (ER±PR pos, HER2 neg); Lum B: (ER±PR pos, HER2 pos); HER2: (ER+PR neg, HER2 pos); or Basal: ER, PR, and HER2 neg.
  • Patients overexpressing HER2 were significantly younger, had more nodal involvement, multicentric/multifocal (Multi) disease, extensive intraductal component (EIC), and lymphovascular invasion (LVI) (all p<0.0001).
  • On multivariate analysis the HER2 subtype had an odds ratio of 2.5 for Multi versus Lum A/B, but HER 2 was not predictive of nodal status.
  • CONCLUSIONS: Even in small breast cancers, presenting features vary with molecular subtype.
  • Unlike Multi, the higher incidence of positive nodes in HER2 patients is explained by traditional prognostic features such as grade, age, and size rather than subtype, suggesting that evaluation of traditional prognostic factors remains valuable in the molecular era.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963488.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Nakayama H, Kato Y, Tsuboi M, Okumura S, Daisaki H, Uehara H, Adachi S, Yoshimura M, Okada M: Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):7573
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy.
  • MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Di Lorenzo G, De Placido S, Cartenì G, Autorino R, Gonnella A, Rizzo M, Perdona S, Ricevuto E, Aieta M, Ewer M: Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e16051
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis.
  • We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent.
  • Patients with pre-existing cardiac risk factors were specifically scrutinized for increased expression of cardiac changes.
  • Among these 17 patients, 12 (70.6%) also experienced left-ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were of classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%).
  • A significant univariate association for predictors of CHF were history of hypertension (p=0.008), history of coronary heart disease (p=0.0005) and prior treatment with an angiotensin converting enzyme inhibitor (ACE) (p= 0.04).
  • Multivariate analysis suggested that a history of coronary artery disease (OR 18, 95% CI, 4-160 p 0.005) and hypertension (OR 3, 95% CI, 1.5-80 p 0.04) were the only significant independent predictors of CHF.
  • CONCLUSIONS: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among 5-yr survivors, the impact of changes in therapy on cause-specific late mortality has not been thoroughly assessed.
  • Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).
  • Additionally, all-cause mortality was significantly lower in more recent eras for 5-year survivors of ALL, AML, Hodgkin, NHL, and CNS tumors, but not neuroblastoma and Ewing's Sarcoma where an increase in cumulative incidence of late mortality was seen in more recent eras.
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).
  • Importantly, however, efforts to reduce the toxicity of more recent therapies have not produced detectable reduction in mortality attributable to other health conditions including sequelae of cancer therapy (non-Recur/Ext causes of death), which would include death from second malignancy, cardiac and pulmonary conditions.
  • Worsening late mortality for 5-year survivors of neuroblastoma and Ewing's sarcoma may be due to improved use of salvage therapies that delay, but do not ultimately prevent death.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Papayannidis C, Iacobucci I, Soverini S, Paolini S, Cilloni D, Messa F, Pane F, Ottaviani E, Baccarani M, Martinelli G: Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol; 2009 May 20;27(15_suppl):7080
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7080 Background: MK-0457 is a pan-aurora kinase inhibitor with activity against wild-type and mutated BCR-ABL, including the T315I form, FLT3, and JAK-2.
  • The third patient, in progression disease, received the 5 days MK-0457 schedule.
  • After one cycle of MK-0457, a complete recovery of the pulmonary disease and a complete hematologic response were obtained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Christy CJ, Rishi M, Schwartz J, Grube BJ, Bossuyt V, Philpotts L, DiGiovanna MP, Tavassoli F, Lannin DR: Association between HER2/neu overexpression and calcifications in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 502 invasive cancers, 165 (33%) had calcifications on mammography and 337 (67%) did not.
  • Among 155 cases with histologic calcifications seen within a ductal intraepithelial neoplasia (DIN) component, there were 45 (29%) that were HER-2/neu positive, compared with 67/414 (16%) that did not have calcifications within DIN (p < 0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • RESULTS: Our data show that ANTP/DN MAML fusion protein, TR4 contains signals for proper cell targeting, internalization and nuclear transport.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A: Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol; 2009 May 20;27(15_suppl):10579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Src kinases play a role in tumor cell migration, invasion and metastasis as well as being part of the signaling cascade for angiogenesis and growth factors.
  • METHODS: The study utilized a Simon Two stage design with the primary endpoint be objective tumor response + prolonged stable disease rate (defined as partial/complete response by RECIST, or stable disease >4 months).
  • Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent.
  • Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request.
  • To date, tumor responses have not been noted; however patients were not selected based on tumor target expression.
  • Further testing may be warranted in selected tumors in combination with chemotherapy given pre-clinical synergy data or in tumors pre-selected for target expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Fuchs E, Köstler W, Horvath R, Hudelist G, Kubista E, Attems J, Zielinski C, Singer CF: Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting. J Clin Oncol; 2009 May 20;27(15_suppl):11110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: ErbB2/CEP17 (R) provided additional predictive value for progression free survival (PFS) and time to first metastasis (TTM), but not for overall survival (OS) (all from start of trastuzumab containing treatment).
  • Significant differences in complete response (B/C: 16.9% vs C:44.4%), partial response (B/C: 20.2% vs. C: 33.3%) and progressive disease (B/C: 27% vs. 11.1%) were noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ayllon J, Banu E, Leviel F, Houillier P, Medioni J, Barrascout E, Oudard S, Maruani G: Bone markers in prostate cancer (PC) patients: Biologic criteria to identify patients at risk of developing distant metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e16069
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16069 Background: Currently, there are no specific serum and/or urinary bone markers able to accurately identify PC patients with hormone-refractory disease and/or those with distant metastases.
  • The serum bone markers investigated were osteogenesis-related [Osteocalcin (OC), procollagen type 1 amino-terminal propeptide (P1NP), bone alkaline phosphatase (BALP)], osteolysis-related [beta collagen 1 carboxyterminal peptide (βCTX), carboxyterminal telopeptide type 1 collagen (1CTP), tartrate resistant acid phosphatase (TRAP)] or osteoclastogenesis-related [osteoprotegerin (OPG)].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Quevedo F, Ashdown ML, Suman VJ, Robinson A, Kottschade LA, Kaur JS, Creagan ET, McWilliams RR, Markovic SN: Possible therapeutic reversal of immune suppression in patients with metastatic melanoma by timed delivery of temozolomide chemotherapy: A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e20013
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All 12 patients (median age 61; 4 female; 7 with M1c disease) exhibited oscillating CRP levels with an average periodicity of 7.8 days.
  • The two patients who remain progression-free for >2 years (1 PR, 1 CR), were treated in the pre-peak section of the CRP cycle, distinctly separate from the other patients treated post CRP-peak (all progressed <5 months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Li J, Bayever E, Gomez J, Yovine A, Monk BJ: Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol; 2009 May 20;27(15_suppl):5550
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
  • 1) the impact of early changes in CA-125 over the subsequent best OR by RECIST;.
  • 2) the concordance between best OR determined by CA-125 and RECIST;.
  • 3) the value of CA-125 to predict radiological response.
  • METHODS: Tumor assessments by imaging and CA-125 were performed at baseline, and every 8 weeks during study in both arms.
  • Radiological tumor assessment, regardless of CA-125 changes, determined the study conduct.
  • Early CA-125 changes were those assessed at the first and second evaluation.
  • RESULTS: Response rate by RECIST (IR)/CA-125 was 28%/48% for T-PLD vs. 19%/33% for PLD.
  • The association between CA-125 and RECIST response was stronger for IA relative to IR/IO, with 79% concordance for both arms, 65% overall positive predictive value (PPV) and 89% negative predictive value (NPV) for IA and 74%/75% concordance, 46%/49% PPV and 93%/92% NPV for IR/IO.
  • Early CA-125 changes were assessed in 514 patients.
  • Early ≥25% CA-125 decreases in the first/second evaluation occurred in 85%/95% of RECIST responders in the T-PLD arm and in 81/82% responders treated with PLD.
  • CONCLUSIONS: The predictive value of CA-125 response was high and similar in both arms.
  • The addition of T to PLD resulted in superior efficacy in this patient population as assessed by IA, IR and IO, with a favorable trend for CA-125 response assessment.
  • RECIST response was preceded by a significant CA-125 decrease in a high proportion of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of squamous cell carcinoma (SCC) were 35.7%, that of adenocarcinoma were 8.1%.
  • FDG-PET detected 100% of intranodal tumor deposits > or =10 mm, whereas tumor deposits smaller than 5 mm were not detected.
  • Particularly, tumor deposits smaller than 5 mm were not detected at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Escofet X, Twine C, Roberts A, Dave B, Rawlinson C, Chan D, Crosby T, Robinson M, Lewis W: Prognostic significance of endoluminal ultrasound defined tumor volume (EDTV) in patients diagnosed with esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15519
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and seventy-four consecutive patients (median age 64y, 128 m) underwent both CT and specialist EUS, and the maximum potential tumour cylinder volume (EDTV) was calculated using the formula πr<sup>2</sup>L (cylinder volume), where r = tumour thickness (cm) and L = total length of disease, including the position and level of both the primary tumour and proximal and distal lymph nodes (cm).
  • RESULTS: Survival was related to EUS T (p=0.013), EUS N (p=0.001), EUS M1a stage (p=0.004), EUS disease length (p=0.001), and EDTV (all patients <25cm<sup>3</sup>, p=0.001, surgical patients <40cm<sup>3</sup>, p=0.036).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962290.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Lu Q, Zhao A, Shen L: Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e15090
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with preoperative chemotherapy had increased steatohepatitis compared with no treatment group (18.5% v 0%, respectively, p=0.0008), the postoperative morbility rate in preoperative chemotherapy (25.9%) was double that of the no-chemotherapy (12.5%), but this difference was not statistically significant (p=0.20).
  • Preoperative chemotherapy was also not associated with 90-day mortality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Wulfing C, Herrmann E, Trojan L, Schrader A, Becker F, Stähler M, Haferkamp A, Legal W, Brenner W, Hartmann A, German Papillary Renal Cancer Study Group: Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort. J Clin Oncol; 2009 May 20;27(15_suppl):5092
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort.
  • : 5092 Background: Papillary renal cell carcinoma (pRCC) is the second most malignant histologic subtype in nephrectomy specimens.
  • Synchronous distant metastases in the entire group occurred in 58 (8.7%) patients and 69 (11.2%) others developed metastatic disease during follow-up.
  • Patients with ≥pT3 were at high risk for metastases (50.6%), while metastatic disease associated with ≤pT2 tumors occurred in 7.8% (p < 0.0001).
  • Once metastatic disease was present, prognosis was poor (5-year CSS: 7.2%).
  • Age was associated with a worse prognosis in the subgroup of ≥pT3 tumors in univariate (p = 0.026), but not in multivariate analysis.
  • Clinical and radiologic follow-ups should be offered in frequent intervals to patients with venous thrombus and/or locally advanced disease.
  • The role of age remains unclear, but should not be underestimated at risk stratification after tumor resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Nadeem A, Wanebo H, Shrayer D, Hazelwood S, Resnick M: Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice. J Clin Oncol; 2009 May 20;27(15_suppl):e14642
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice.
  • : e14642 Introduction: The ceramides are a major signaling pathway for apoptosis in cells undergoing stress or exposure to chemotherapy.
  • We have demonstrated synergistic anti-tumor effects of combining C6 ceramide with paclitaxel, doxorubicin and cisplatin and are currently addressing the question; does C6 augment activity of all the major classes of drugs?
  • Backround: Currently the in vivo anti-tumor effects of C6 with oxaliplatin and Gemcitabine.
  • METHODS: Invivo experiments SCID/Beige/Taconic male mice inoculated S.C. with 2X106 L3.6 pancreatic cells were treated 4 days post tumor implant with trice weekly (3x/wk) intraperitoneal (IP) injections of paclitaxel (P) 3.0 m/kg, oxaliplatin (OX) 2.5 mg/kg, cisplatin (CP) 2.5 mg/kg, Gemcitabine (Gem) 10 mg/kg with/without ceramide 10 mg/kg.
  • Mice were observed for 6 weeks and were autopsied when near death. (All controls died by 3<sup>rd</sup> week).
  • Maximum tumor volume, tumor weight; body weight and survival were recorded.
  • RESULTS: Combination with C6 ceramide augmented the tumor reduction obtained by chemotherapy alone by 57% (while preserving body weight), and increased 6 week survival from 0% (Chemotherapy alone) to 60% with combined therapy.
  • Mean survival was increased from 25 to 37 days.
  • Although short term immunohistochemical studies suggested enhanced apoptosis and increased caspase 3 production by ceramide combinations it may actually be independent of capase activation and mitochondrial activation.
  • CONCLUSIONS: Combination therapy with the apoptotic signal C6 ceramide significantly enhanced the anti-tumor effects of the anti microtubule, alkylating Paclitaxel a DNA interculating antibiotic (doxorubicin) the alkylating/DNA adducting agents (cisplatin, oxaliplatin) and an anti metabolite (gemcitabine) suggesting generation of broad based apoptotic signals which interact with major cancer drug classes (tested).
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964231.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Pavoni-Ferreira PC, Petrilli AS, Alves MT, Jesus-Garcia Filho R, Toledo SR: Angiogenic biomaker study in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.
  • Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.
  • RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • Additionally, 36.0% of the patients in the phenytoin group had dose adjustments not related to breakthrough seizures compared to only 9.8% in the levetiracetam group (p = 0.010).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Key eligibility criteria were untreated locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0-2, tumor not abutting major blood vessels, no uncontrolled HTN (systolic >150mmHg and/or diastolic >100mmHg) or active cardiovascular disease at baseline.
  • Non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients must be ≥18 years with previously treated NPC or other incurable solid tumors; must have measurable disease according to RECIST, ECOG 0-1, and adequate bone marrow, hepatic and renal function.
  • Majority of stable disease occurred in NPC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A, Eastern Cooperative Oncology Group: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol; 2009 May 20;27(15_suppl):6020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group.
  • : 6020 Background: B, inhibits activation of NF- κβ and inhibits growth of SCCHN cell lines.
  • To date, RR low but prolonged stable disease noted in some pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wang XS, Williams LA, Johnson VE, Mao L, Krishnan S, Liao Z, Mobley G, Cleeland CS: Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum samples were tested weekly during therapy for changes in concentration levels of inflammatory cytokines (interleukin [IL]-6, IL-8, IL-10, IL-1 receptor antagonist [IL-1RA], vascular endothelial growth factor [VEGF], and soluble tumor necrosis factor receptor type 1 [sTNF-R1]) via enzyme-linked immunosorbent assay (ELISA).
  • Symptom responses were modeled using longitudinal ordinal probit regression functions that included these serum cytokine values, along with age, cancer type, prechemotherapy status, and race (non-Hispanic white vs. others), as explanatory variables.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961980.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H: A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7021
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7021 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest.
  • Overall response rate is 31% (13% CR/CRp, 5% PR and 13% HI).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Grimley PM, Matsuno R, Anderson WF: Population profiles of extra-ovarian and ovarian serous adenocarcinomas: Comparisons with grade stratification. J Clin Oncol; 2009 May 20;27(15_suppl):e16506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence rates (IR) stratified by grade were compared by year or age of diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Kiers HA: Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms. Psychometrika; 2006 Jun;71(2):231-256
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms.
  • : Prior to a three-way component analysis of a three-way data set, it is customary to preprocess the data by centering and/or rescaling them.
  • Harshman and Lundy (1984) considered that three-way data actually consist of a three-way model part, which in fact pertains to ratio scale measurements, as well as additive "offset" terms that turn the ratio scale measurements into interval scale measurements.
  • They mentioned that such offset terms might be estimated by incorporating additional components in the model, but discarded this idea in favor of an approach to remove such terms from the model by means of centering.
  • Then estimates for the three-way component model parameters are obtained by analyzing the centered data.
  • In the present paper, the possibility of actually estimating the offset terms is taken up again.
  • First, it is mentioned in which cases such offset terms can be estimated uniquely.
  • Next, procedures are offered for estimating model parameters and offset parameters simultaneously, as well as successively (i.e., providing offset term estimates after the three-way model parameters have been estimated in the traditional way on the basis of the centered data).
  • These procedures are provided for both the CANDECOMP/PARAFAC model and the Tucker3 model extended with offset terms.
  • The successive and the simultaneous approaches for estimating model and offset parameters have been compared on the basis of simulated data.
  • It was found that both procedures perform well when the fitted model captures at least all offset terms actually underlying the data.
  • The simultaneous procedures performed slightly better than the successive procedures.
  • If fewer offset terms are fitted than there are underlying the model, the results are considerably poorer, but in these cases the successive procedures performed better than the simultaneous ones.
  • All in all, it can be concluded that the traditional approach for estimating model parameters can hardly be improved upon, and that offset terms can sufficiently well be estimated by the proposed successive approach, which is a simple extension of the traditional approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197950.001).
  • [ISSN] 1860-0980
  • [Journal-full-title] Psychometrika
  • [ISO-abbreviation] Psychometrika
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; additive terms / preprocessing / three-way component models
  •  go-up   go-down


81. Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L, I-SPY TRIAL Investigators: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. J Clin Oncol; 2009 May 20;27(15_suppl):1503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relationship to breast density and subtype is currently being assessed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E, ITMO Study Group: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5099
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
  • Therapy continued until progression of disease or unacceptable toxicity.
  • Eligible pts had histological diagnosis of RCC, ECOG 0-2, no brain metastases, measurable disease and any Motzer's score.
  • Response rates (all partial responses, PR) were 23 % and 10 % in arm A and B respectively.
  • Overall disease control rates (PR + stable disease SD) were 81 % versus 74 %.
  • CONCLUSIONS: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17575 Background: We (MC) previously established a definition of laboratory (LTLS) and clinical TLS (CTLS) and associated grading system (Cairo et al, BJH. 2004).
  • Additionally, we recently reported an evidence based review of guidelines for the P and T of TLS (Coiffier et al, J Clin Oncol. 2008).
  • Rasburicase (R), a recombinant urate oxidase, results in a more rapid and total reduction of uric acid (UA) compared to allopurinol (A) in children at high-risk of TLS (Goldman/Cairo et al, Blood.
  • 2001) and a rapid reduction in UA in adults at high-risk of TLS (Coiffier et al, J Clin Oncol. 2003).
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Blay J, Penel N, Italiano A, Duffaud F, Rios M, Collard O, Bertucci F, Isambert N, Chaigneau L, Zintl P: Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program. J Clin Oncol; 2009 May 20;27(15_suppl):10574
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Best response reported were PR, n=15 (8%), SD, n=68 (36%) and PD, n=94 (50%), NE, n=11 (6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African American (AA) women with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22119
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it remains to be determined whether p53 status would add prognostic value beyond the commonly used factors of stage and Intrinsic Subtype Classification (subtype).
  • METHODS: Cox proportional hazards regression models [results reported as hazard ratios (HR) with 95% confidence intervals (CI)] were used to select and evaluate prognostic factors [including stage, age, tumor grade of differentiation (grade), p53 status, subtype, & ER/PR status] for all-cause mortality in 331 consecutively treated AA women with breast cancer [42 months follow-up] and known subtype [luminal A = ER+, &/or PR+, & HER2-; luminal B = ER+, &/or PR+, & HER2+; HER2+ = ER-, PR-, & HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK) 5/6+ &/or HER1+; & unclassified = negative for all 5 markers] and p53 [Pab1801 antibody] immunohistochemical status.
  • However, 59% of p53+ women were ER/PR negative [Odds Ratio (OR), 0.37; 95% CI, 0.22-0.54; p=0.0003] and hence endocrine therapy was significantly less frequent in p53+ women [OR, 0.40; 95% CI, 0.23-0.69; p=0.0008].
  • Baseline prognostic factors were: stage [(II-IV/I) HR, 2.29; 95% CI, 1.86-2.81; p<0.0001]; age [HR, 1.003 per year; 95% CI, 0.99-1.02; p=0.697]; grade [(high/low) HR, 1.70; 95% CI, 1.22-2.37; p=0.0008]; p53 status [(±) HR, 1.76; 95% CI, 1.15-2.72; p=0.012]; subtype [(all other/luminal A) HR, 1.33; 95% CI, 1.14-1.55; p=0.0004]; ER/PR status [(±) HR, 0.47; 95% CI, 0.32-0.69; p=0.0001].
  • Cox multivariable models indicated that p53 status [HR, 1.59; 95% CI, 1.01-2.51; p=0.044] remained a significant prognostic factor when considered with stage [HR, 2.20; 95% CI, 1.71-2.84; p<0.001] and subtype [HR, 1.24; 95% CI, 1.04-1.49; p=0.016] and the other above-mentioned factors.
  • CONCLUSIONS: Study results indicate that p53 status should be included with stage and subtype as markers to assess prognosis in AA women with breast cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Godoy J, Cardona AF, Cáceres H, Otero JM, Lujan M, Lopera D, Pacheco JO, Spath A, Gis P: Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e16150
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study).
  • : e16150 Background: Renal cell carcinoma has increased its incidence by 126% since 1950.
  • A local study developed a complete economic evaluation of sunitinib versus IFN in first-line treatment of mRCC in Colombia, finding that sunitinib was more cost-useful and cost-effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Kolinsky KD, Zhang Y, Packman K, Higgins B: In vivo activity of R1530 (R) alone and in combination with docetaxel (D) and bevacizumab (B) in a prostate carcinoma (PCa) xenograft model. J Clin Oncol; 2009 May 20;27(15_suppl):e16124
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its inhibitory profile includes several kinases that play critical roles in cancer cell growth and division leading to disruption at M-phase and antiangiogenic effects.
  • MED R + 2/3 OD D gave ILS statistically better (sb) than singlets but TGI was sb than MED R but not the D singlet.
  • TGI and ILS of 2/3 OD R + 2/3 OD D was sb than the 2/3 OD D + OD B but not the 2/3 OD R + B doublet.
  • In general, the results demonstrate that the shared mechanism of mitotic disruption by R and D do not render antagonism, but in fact, allow for potentiated TGI and ILS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Bosl GJ, Motzer RJ: Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts. J Clin Oncol; 2009 May 20;27(15_suppl):5027
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts.
  • METHODS: Phase I/II trial of TI-CE conducted in GCT pts with progressive disease following chemotherapy and unfavorable prognostic features (extragonadal primary site, IR to first-line therapy, or relapse/IR to ifosfamide/cisplatin-based conventional-dose salvage).
  • 5-yr disease-free survival (DFS) was 47% and overall survival 52% with a median follow-up of 61 months (m).
  • 5/21 (24%) primary mediastinal NSGCT and 2/7 late relapses are continuously disease-free.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902-10).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R: Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2529
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • R is an oral mTOR inhibitor that demonstrates synergy with P in pre-clinical models, possibly by decreasing resistance to apoptosis.
  • In pts with prostate cancer (all previously pretreated with D) PSA declines of >50% occurred in 3/5 pts treated with >2 cycles; 1/7 pts with colon cancer had a PR and 3/7 pts with colon cancer had stable disease (SD) > 8 cycles; 1/3 pts with ampullary ca had a PR and a pt with cervical ca had SD x10 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Mishra A, Singh VP, Verma V: Environmental effects on head and neck cancer in India. J Clin Oncol; 2009 May 20;27(15_suppl):e17059
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Beans, peas, and corn was not common while beef and pork consumption rare owing .

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961820.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Costello BA, Hecht JR, Grothey A: Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. J Clin Oncol; 2009 May 20;27(15_suppl):4054
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Historically, clinical trials have not required tissue samples to be tested for KRAS mutation status as a condition of enrollment.
  • Further, our results suggest that there is not an inherent systemic bias influencing any potentially observed differences in PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Besse B, Almokadem S, Planchard D, Chico I, Tsao CL, Ringeisen F, Soria J, Belani CP: Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13513
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC).
  • Partial response was seen in 6 pts and stable disease in 12 out of 18 pts who were evaluable for response by RECIST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961304.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Dhruva NS, Stinchcombe TE, Walko CM, Socinski MA, Bernard S, Kim WY, Keller K, Hilbun LR, Dees EC: Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e13521
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13521 Background: Sorafenib had demonstrated single agent activity in non-small cell and small cell lung cancer.
  • Responses observed were: PR (n=3) (all arm C), and SD (n=6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Ray-Coquard IL, Provençal J, Hardy-Bessard AC, Bachelot T, Coeffic D, Jacquin JP, Guastalla JP, Agostini C, Pivot X, Bajard A, Pérol D: Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20566
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The planned sample size was 396 evaluable patients based on a minimum expected difference in mean of 0.5 ± 1.6 on a scale from 1 (a lot) to 7 (not at all) with 5% two-sided α error and 85% power.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, Bourquelot PM, San Miguel JF: Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):8542
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Cohort 2, eight patients were treated at the dose level of 10 mg of panobinostat, with one single DLT: a Gr 1 increase of QT interval duration was detected on Day 3, persisting on Day 8 with therapy withheld, meeting DLT definition although not deemed clinically relevant.
  • All, but fever in one patient, were assessed by the investigator as not study drug related.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Samelis GF, Tsiakou A, Karamanidi M, Pelechrini M, Zaganides A, Ekmektzoglou K: Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival. J Clin Oncol; 2009 May 20;27(15_suppl):e15143
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival.
  • Bevacizumab treatment was continuously dispensed after disease progression and only other combined drugs were altered.
  • Progression free survival (PFS) was 17 months in first line setting (overall survival (OS) not reached yet) o, and for the age group >69 and <69 it was 23 and 16 months respectively (p=0.4565).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Evens AM, David KA, Helenowski I, Kircher SM, Mauro L, Gimelfarb A, Hattersley E, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):8510
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors.
  • The impact of rituximab (RTX) on the prognosis or outcome of PTLD is not known.
  • RESULTS: 81 PTLD pts were identified (SOT: 47 kidney ± pancreas, 4 pancreas, 17 liver, 8 heart, 5 lung) with median age at diagnosis (dx) of 48 yrs (range 20-72).
  • 1) PS, 2) serum albumin, 3) >1 EN site, 4) marrow involvement, 5) CNS disease and 6) RTX as part of initial therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):534
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously found that the baseline serum bone resorption marker, beta C-terminal telopeptides of type I collagen (B-CTx), was associated with bone-only first relapse, and that higher levels of insulin secretion as estimated by c-peptide level was associated with reduced event-free survival (EFS).
  • Recurrence-free survival (RFS), time from randomization to recurrence of the primary disease alone, was a secondary endpoint.
  • Continuous D was not associated with RFS of any relapse (p = 0.57), bone only relapse (p = 0.19), bone + other site of relapse (p = 0.73), or all bone relapse types (p = 0.66).
  • D was not associated with EFS (0.43), even when adjusted by season (p = 0.64), level deficiency/insufficiency vs sufficiency/toxicity (p = 0.69), age (p = 0.54), and BMI (p = 0.32).
  • CONCLUSIONS: D was not associated with EFS or RFS in postmenopausal breast cancer patients in this well controlled hormonal therapy study, a result consistent with some, but not all, studies of this issue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement